Quick generic drug reminder: If you, a family member or other loved uses antipsychotic medications, you may already have October 23rd circled on your calendar, but if not, here’s the head’s up. Eli Lilly’s anti-psychotic blockbuster Zyprexa is finally losing its patent protection in less than three weeks, opening the market to what is hopefully cheaper and more affordable generic competitors.
Yes, you heard right. Zyprexa, which is the best-selling drug in Eli Lilly’s history, will finally be open to generic competitors in less than three weeks. Considering a thirty-day supply of brand-name Zyprexa is currently running almost $400, this could easily be a huge savings for many patients who use antipsychotic medication.
Of course, even though Zyprexa is losing its patent protection, it doesn’t mean that we’ll be getting a cheaper, more affordable generic version of the drug right away, and we’re still not sure who is going to be the first company to get a generic version of Zyprexa onto the market and when that is going to be. (Money’s currently on Indian generic drug giant Dr. Reddy’s to be the first launch a generic version of Zyprexa.)
You can be sure that we’ll be keeping tabs on this one!
Do you or a loved one use Zyprexa? Tell us about it!
Related posts:
- Generic Drug Reminder: Lipitor, Plavix, Zyprexa and Levaquin To Go Generic Next Year
- Generic Drug Alert: FDA Will Not Extend Patent on Treximet Migraine Drug, Is a Cheaper Generic On the Way?
- Generic Drug Alert: FDA Approves Generic Version of Lithobid
- Thought Viagra Was Going Generic Next Year? Pfizer Fights to Keep Its Patent Until 2019
- Huge Generic Drug News! FDA Grants Tentative Approval for Generic Version of Cholesterol Drug Crestor
Loading ...
Follow Us!